BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35442423)

  • 1. Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.
    Singh S; Lee N; Pedroza DA; Bado IL; Hamor C; Zhang L; Aguirre S; Hu J; Shen Y; Xu Y; Gao Y; Zhao N; Chen SH; Wan YW; Liu Z; Chang JT; Hollern D; Perou CM; Zhang XHF; Rosen JM
    Cancer Res; 2022 Jun; 82(12):2281-2297. PubMed ID: 35442423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
    Wang G; Romero Y; Thevarajan I; Zolkiewska A
    Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer.
    Adewunmi O; Shen Y; Zhang XH; Rosen JM
    Cancer Immunol Res; 2023 Nov; 11(11):1462-1479. PubMed ID: 37603945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
    Sami E; Paul BT; Koziol JA; ElShamy WM
    Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
    Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
    Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
    Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
    Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
    Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
    J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
    Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
    Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
    Frankenberger C; Rabe D; Bainer R; Sankarasharma D; Chada K; Krausz T; Gilad Y; Becker L; Rosner MR
    Cancer Res; 2015 Oct; 75(19):4063-73. PubMed ID: 26238785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
    Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
    Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
    Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
    Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
    Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.